Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine

Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). To assess COVID-19 incide...

Descripción completa

Detalles Bibliográficos
Autores: Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291, Molina Romero, Israel|||0000-0001-6642-7515, Martinez, Elisenda, Roman-Viñas, Ramón, Sánchez Montalvá, Adrián|||0000-0002-2194-5447, Fibla, Joan|||0000-0002-3255-2227, Pontes García, Caridad|||0000-0002-3274-6048, Velasco Muñoz, César
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:237590
Acceso en línea:https://ddd.uab.cat/record/237590
https://dx.doi.org/urn:doi:10.2807/1560-7917.ES.2021.26.9.2001202
Access Level:acceso abierto
Palabra clave:SARS-CoV-2
COVID-19
Coronavirus
Chloroquine
Hydroxychloroquine
Pre-exposure prophylaxis
id ES_cb1ed79b2d483f53cd829fc4bbb8b451
oai_identifier_str oai:ddd.uab.cat:237590
network_acronym_str ES
network_name_str España
repository_id_str
spelling Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquineresults from a population-based prospective cohort in Catalonia, Spain, 2020Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291Molina Romero, Israel|||0000-0001-6642-7515Martinez, ElisendaRoman-Viñas, RamónSánchez Montalvá, Adrián|||0000-0002-2194-5447Fibla, Joan|||0000-0002-3255-2227Pontes García, Caridad|||0000-0002-3274-6048Velasco Muñoz, CésarSARS-CoV-2COVID-19CoronavirusChloroquineHydroxychloroquinePre-exposure prophylaxisSeveral clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83-1.44; p = 0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91-2.34; p = 0.10). Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/237590https://dx.doi.org/urn:doi:10.2807/1560-7917.ES.2021.26.9.2001202reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2375902026-06-06T12:50:31Z
dc.title.none.fl_str_mv Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
results from a population-based prospective cohort in Catalonia, Spain, 2020
title Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
spellingShingle Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
SARS-CoV-2
COVID-19
Coronavirus
Chloroquine
Hydroxychloroquine
Pre-exposure prophylaxis
title_short Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
title_full Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
title_fullStr Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
title_full_unstemmed Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
title_sort Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine
dc.creator.none.fl_str_mv Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
Molina Romero, Israel|||0000-0001-6642-7515
Martinez, Elisenda
Roman-Viñas, Ramón
Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Fibla, Joan|||0000-0002-3255-2227
Pontes García, Caridad|||0000-0002-3274-6048
Velasco Muñoz, César
author Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
author_facet Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
Molina Romero, Israel|||0000-0001-6642-7515
Martinez, Elisenda
Roman-Viñas, Ramón
Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Fibla, Joan|||0000-0002-3255-2227
Pontes García, Caridad|||0000-0002-3274-6048
Velasco Muñoz, César
author_role author
author2 Molina Romero, Israel|||0000-0001-6642-7515
Martinez, Elisenda
Roman-Viñas, Ramón
Sánchez Montalvá, Adrián|||0000-0002-2194-5447
Fibla, Joan|||0000-0002-3255-2227
Pontes García, Caridad|||0000-0002-3274-6048
Velasco Muñoz, César
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv SARS-CoV-2
COVID-19
Coronavirus
Chloroquine
Hydroxychloroquine
Pre-exposure prophylaxis
topic SARS-CoV-2
COVID-19
Coronavirus
Chloroquine
Hydroxychloroquine
Pre-exposure prophylaxis
description Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19). To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine. We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes. We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83-1.44; p = 0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91-2.34; p = 0.10). Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/237590
https://dx.doi.org/urn:doi:10.2807/1560-7917.ES.2021.26.9.2001202
url https://ddd.uab.cat/record/237590
https://dx.doi.org/urn:doi:10.2807/1560-7917.ES.2021.26.9.2001202
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419560373846016
score 15.301629

Similares en LA Referencia